Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06326346 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GIST Oral Paclitaxel(Liporaxel)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2024 to Nov 20, 2024
    • Site details revised
    v4
  2. Start date: Jun 1, 2024 to Aug 1, 2024v3
  3. Eligibility criteria revised
    • Study title revised
    • Study description expanded, about 2 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression.
Trial Details
NCT Number NCT06326346
Lead Sponsor Asan Medical Center
Conditions
(from sponsor)		 Gastrointestinal Stromal Tumors
Related terms Gastrointestinal Stromal Tumors
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov